Sonata Software (SONSOF)

CMP: ₹ 623

Target: ₹ 760 (22%)

Target Period: 12 months

November 8, 2024

BUY

CICI direc



Particulars	
Market Cap (₹ Crore)	17,331
Total Debt (₹ Crore)	674
Cash and Invts (₹ Crore)	1,097
EV (₹ Crore)	16,908
52 week H/L	870 / 469
Equity capital (₹ Crore)	27.8
Face value	1.0
Shareholding pattern	

Sep-23 Dec-23 Mar-24 June-24 Promoters 28.2 28.2 28.2 28.2 28.2 FII 15.0 14.5 13.9 12.4 12.1 DII 16.4 23.4 17.6 17.6 21.6 Other 40.5 39.8 40.3 37.9 36.3 **Price Chart**

26000 800 600 400 200 0 1000 16000 11000 0 100

Key risks

- Lower than expected revenue due to delay in deal closures
- Lower than expected margin growth

Research Analyst

Bhupendra Tiwary, CFA bhupendra.tiwary@icicisecurities.com

CA Anjini Sharma anjini.sharma@icicisecurities.com

Deep Thosani deep.thosani@icicisecurities.com

Steady show! H2 to witness growth recovery...

About the stock: Sonata Software (Sonata) provides IT services and product licensing services to its clients in BFSI, HLS (Healthcare & Lifesciences), RMD (Retail, Manufacturing, Travel & Distribution & TMT) segments.

Q2FY25 Performance: Revenue for International IT services (IITS) at US\$ 84.6 mn, was up 2.3% QoQ/4.6% YoY (up 1.5% QoQ/3.7% YoY in CC terms). IITS EBITDA came at ₹128.9 crore, with an EBITDA margin of 18.2%, down ~52 bps QoQ. At the company level, revenue was ₹ 2,170 crore, down 14.5% QoQ/ up 13.4% YoY. EBITDA came at ₹177.2 crore, flattish QoQ translating to an EBITDA margin of 8.2%, up 120 bps QoQ while PAT (before exceptional items) stood at ₹106.5 crore.

Investment Rationale:

- H2 to be better, positive long-term outlook maintained: Sonata indicated that it expects H2 to be better than H1 on the back of the large deal ramp up. It also reiterated its ambition of achieving US\$ 1.5 bn revenues by FY27. While TMT and Retail remained weak, BFSI, Healthcare & Life Sciences (HLS) segment along with large deals from the Hi-Tech segment, drove the growth in the quarter. With a strong deal pipeline across HLS, banking and Hi Tech, the company is poised for a future growth. We expect IT services to grow at a CAGR of 11.6% over FY24-27E in dollar terms with ~8% growth in FY25 (largely back ended).
- Margin recovery likely in FY26: The management Indicated that margins headwinds in FY25 include ~200 bps on account of investment in the business for and likely ~110 bps from the wage hike impact. It remained hopeful of achieving its steady state margins of low 20s by Q1FY26, given the large deal ramp ups and absorption of residual wage hike (50-60 bps) by then.
- Large deal wins, and strong GenAl deal pipeline to sustain growth: The
 company for the second consecutive quarter won 3 large deals.
 Additionally, it also won 2 midsized deals. It reported a strong GenAl deal
 pipeline of US\$ 67 million across 110 clients. It is also actively working to
 increase its GenAl capabilities as 83% of its employees are GenAl trained
 vs. 67% in Q1.

Rating and Target Price

- Sonata's long term growth momentum hinges on its large deal wins, robust pipeline, and advancements in Al. We maintain a positive outlook on the company, factoring in the near-term margin challenges amid ongoing growth initiatives
- We maintain a BUY rating, valuing it at a target price of ₹ 760, with a multiple of 28x P/E on FY27E EPS.

Key Financial Summary

(₹ Crore)	FY22	FY23	FY24	5 year CAGR (FY19-24)	FY25E	FY26E	FY27E	2 year CAGR (FY24-26E)
Net Sales	5,553	7,449	8,613	23.8%	9,793	11,235	12,880	14.4%
EBITDA	464	604	727	3.5%	787	1,011	1,185	17.7%
EBITDA Margin (%)	8.4	8.1	8.4		8.0	9.0	9.2	
PAT	376	452	308		494	684	828	
Adjusted PAT	376	452	483	14.4%	494	684	828	19.7%
EPS (Rs.)	27.2	32.6	11.1		17.8	24.6	29.8	
P/E (x)	23.0	19.1	35.9		35.0	25.3	20.9	
RoNW (%)	34.2	34.7	21.9		29.3	32.1	31.0	
RoCE (%)	39.8	25.9	31.4		28.2	31.7	32.2	

Performance highlights and outlook

- Revenue Performance: Revenue for IITS services in Q2FY25 stood at US\$ 84.6 mn, up 2.3% QoQ / 4.6% YoY (up 1.5% QoQ/ 3.7% YoY in CC terms). In rupee terms, the IITS revenue stood at ₹708 crore, up 2.9% QoQ. At the company level the revenue came at ₹2,170 crore, down 14.5% QoQ/ up 13.4% YoY. The QoQ decline in company level revenues was owing to seasonality in its product business.
- Margin Performance: IITS reported an EBITDA margin of ₹128.9 crore, marginally up QoQ. The EBITDA margin came at 18.2%, down ~52 bps, due to the wage hike impact (~110 bps) which was offset by the savings in operational improvements and SG&A leverage in the quarter. The PAT for the quarter stood at ₹105.6 crore, translating to a PAT margin of 4.9%, up ~70 bps QoQ.
- Geography Performance: Geography wise, on a QoQ basis, the growth
 was led Europe (14% of the mix) and USA (72% of the mix) up 10.2%
 and 2.3% respectively, while RoW (14% of the mix) declined by 4.5%
 QoQ. The US geography is expected to grow faster than the other
 geographies.
- Segmental Performance and Outlook: Segment wise, BFSI (22% of the mix) Emerging (5% of the mix), Healthcare (10% of the mix) grew by 40.6%, 28% and 2.3% respectively. Whereas, TMT (32% of the mix), Retail & Manufacturing (31% of the mix), declined by 9.07% and 6.73% respectively.
 - BFSI/HLS: The management mentioned that its healthcare life sciences and banking segments combined now contribute ~32% to its revenue, up from ~13% ten quarters back. Both the segments have cumulatively added ~18% of its client revenue, over the last 2.5 years back. They further expect to achieve a cumulative revenue of ₹ 25 crores from the segments. Moving forward, the company expects to achieve growth from these segments.
 - Retail & Manufacturing: This segment saw a substantial decline because of the discretionary spend slowdown and delayed deal closures. The management mentioned that all the consumer facing companies are expected to remain muted for the next 2-3 quarters.
 - Hi-Tech: The large deal wins in the quarter are seen from HiTech and the Healthcare segment, however apart from that it has seen a decline in the quarter.
- Revenue and Margin Outlook: The management aims to level the EBITDA margins back to low 20s from its current 18.5% by Q1FY25. This growth will be achieved on the back of large deals ramp up and absorption of the wage hikes declared in the quarter. It reiterated its aspiration of achieving US\$ 1.5 bn (₹150 crore) at the end of FY27 for the international business. It also indicated that margins for Q3 are expected to be muted due to the residual impact of wage hikes (40-50 bps). Nonetheless, the company is expected to see a better H2FY25, both on revenues and margins front.
- GenAI/AI: On the AI front the company aims to achieve its target of generating ~20% of its revenues from AI enabled services by the end of CY27. They're leveraging their Harmoni.AI platform actively across clients and continue to deepen the partnership with hyper-scalers (for AI, Gen AI products). On the people front ~83% of its employees are GenAI trained, a significant increase from 67% last quarter.
- Microsoft Fabric: The company since its launch in Nov'23 saw a significant
 pipeline build amounting to US\$ 91 mn, across 110 clients. In the quarter
 it won one of its two mid-sized deal in the data transformation space
 leveraging Microsoft Fabric.

- Deal Wins and Pipeline: Sonata in the quarter won 3 large deals and 2 mid-sized deals. The company has ~36% of its large deal pipeline with Fortune 500 companies.
- Client mix: The top 10 clients (63% of the mix), top 20 clients (77% of the mix) grew by 8% and 15% respectively. It added 8 new clients in the quarter, down from 14 in the previous quarter.
- Cloud & Data: The cloud and data pipeline is now ~51% of its overall pipeline, up from 15%, 2.5 years back. They're seeing increased traction in the segment as it saw a growth of ~120% over the previous year.
- Attrition rate: The headcount in the quarter stood at 6,485 employees, a net increase of 284 employees. The attrition for the quarter stood flat at

Exhibit 1: Quarter Performar	nce					
	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comments
						IT services reported 1.5% QoQ CC growth while rupee
Revenue	2,170	1,913	13.5	2,527	(14.1)	revenues were up by 2.3% QoQ while Domestic
						Products business declined by 21% QoQ
Employee expenses	405	340	19.1	369	9.6	
Purchase of stock-in trade	1,399	1,210	15.6	1,787	(21.7)	
Gross Margin	366	363	0.9	371	(1.3)	
Gross margin (%)	16.9	19.0	-210 bps	14.7	219 bps	
Other expenses	189	165	14.1	195	(3.1)	
EBITDA	177	197	(10.2)	176	0.6	
EBITDA Margin (%)	8.2	10 3	-215 bps	7.0	120 bp:	EBITDA margins for IT services declined ~52 bps QoQ to
ZETT E7 (Margin (7.0)						18.2% due to the wage hikes impact in the quarter
Depreciation & amortisation	33	33	(1.3)	33	(1.1)	
EBIT	144	164	(12.0)	143	1.0	
EBIT Margin (%)	6.7	8.6	-192 bps	5.7	100 bp:	S
Other income (less interest)	0	3	(99.6)	(1)	(100.9)	
PBT	144	167	(13.3)	142	1.8	
Tax paid	38	42	(10.6)	36	4.8	
PAT	106	124	(14.2)	106	0.6	

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 2: Profit and loss statement					
(Year-end March)	FY24	FY25E	FY26E	FY27E	
Total Revenues	8,613	9,793	11,235	12,880	
Growth (%)	15.6	13.7	14.7	14.6	
Total Op Expenditure	7,886	9,005	10,224	11,695	
EBITDA	727	787	1,011	1,185	
Growth (%)	20.4	8.2	28.4	17.2	
Depr & Amortization	132	137	146	167	
Other Income	126	76	93	130	
Interest costs	85	72	58	58	
PBT before Excep Items	636	655	900	1,090	
Growth (%)	6.5	2.9	37.5	21.1	
Tax	153	160	216	262	
PAT before Excep Items	483	494	684	828	
Exceptional items	(175)	-	-	-	
PAT before MI	308	494	684	828	
Minority Int & Pft. from ass	-	-	-	-	
PAT	308	494	684	828	
Growth (%)	(32)	60	38	21	
EPS	11.1	17.8	24.6	29.8	
EPS (Growth %)	(66)	60	38	21	

Source:	Company.	ICICI	Direct	Research

Exhibit 4: Balance Sheet				₹ crore
(Year-end March)	FY24	FY25E	FY26E	FY27E
Equity	28	28	28	28
Reserves & Surplus	1,379	1,657	2,102	2,640
Networth	1,406	1,685	2,130	2,668
Minority Interest	-	-	-	-
LT liabilties & provisions	219	219	219	219
Total Debt	674	674	674	674
Source of funds	2,299	2,578	3,023	3,561
Assets				
Net fixed assets	558	478	396	297
Goodwill	1,113	1,113	1,113	1,113
Long term loans	-	-	-	-
Other non current assets	403	444	494	552
Loans and advances	-	-	-	-
Inventories	98	111	128	147
Current Investments	232	232	232	232
Debtors	1,605	1,825	2,094	2,400
Cash & Cash equivalents	865	1,301	1,924	2,670
Other current assets	275	313	359	412
Current liabilities	2,813	3,198	3,669	4,207
Provisions	37	42	48	55
Net current assets	226	542	1,019	1,599
Application of funds	2,299	2,578	3,023	3,561

Source: Company, ICICI Direct Research

Exhibit 3: Cash flow stateme	nt		₹cr	ore
(Year-end March)	FY24	FY25E	FY26E	FY27E
Net profit before Tax	461	655	900	1,090
Depreciation & Amortization	132	137	146	167
WC changes	(209)	78	95	109
Other non cash adju.	159	(5)	(35)	(72)
Income taxes paid	(262)	(160)	(216)	(262)
CF from Operations	281	705	891	1,032
Capital expenditure	0	(34)	(39)	(45)
Δ in investments	(88)	-	-	-
Other investing cash flow	33	76	93	130
CF from Investing Activities	(54)	42	53	85
Issue of equity	14	-	-	-
Δ in debt funds/lease liab.	139	(24)	(24)	(24)
Dividends paid	(215)	(216)	(239)	(290)
Other financing cash flow	(46)	(72)	(58)	(58)
CF from Financial Activities	(109)	(311)	(321)	(372)
Δ in cash & bank balance	118	436	623	746
Effect of exchange rate	1	-	-	-
Opening cash	417	865	1,301	1,924
Closing cash	865	1,301	1,924	2,670

Source: Company, ICICI Direct Research

Exhibit 5: Key ratios				
(Year-end March)	FY24	FY25E	FY26E	FY27E
Per share data (₹)				
EPS-diluted	11.1	17.8	24.6	29.8
Cash per share	31.1	46.8	69.2	96.0
BV	50.6	60.6	76.6	96.0
DPS	7.9	7.8	8.6	10.4
Operating Ratios				
EBITDA Margin	8.4	8.0	9.0	9.2
Adjusted PBT Margin	7.4	6.7	8.0	8.5
Adjusted PAT Margin	3.6	5.0	6.1	6.4
Return Ratios (%)				
RoNW	21.9	29.3	32.1	31.0
RoCE	31.4	28.2	31.7	32.2
RoIC	49.5	62.2	99.8	154.4
Valuation Ratios (x)				
P/E	35.9	35.0	25.3	20.9
EV / EBITDA	23.2	20.9	15.7	12.7
Price to Book Value	12.3	10.3	8.1	6.5
EV/Total Revenues	2.0	1.7	1.4	1.2
MCap/Total Revenues	2.0	1.8	1.5	1.3
Turnover Ratios				
Debtor days	68	68	68	68
Creditors days	60	60	60	60
Solvency Ratios				
Debt/EBITDA	0.9	0.9	0.7	0.6
Total Debt / Equity	0.5	0.4	0.3	0.3
Current Ratio	1.1	1.2	1.3	1.4
Quick Ratio	1.0	1.1	1.2	1.3

Source: Company, ICICI Direct Research



RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Bhupendra Tiwary, CFA, MBA (Finance), Anjini Sharma, CA, Deep Thosani, MBA (Finance) Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: 167120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat receipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.